Replies to post #108850 on NanoViricides Inc. (NNVC)

[FORZANANO]

NNVC is exhibited increasingly with a "strong buy":

NanoViricides Announces that a Research Report on the Company has been Published By Midtown Partners, Inc., a New York Invest...[/b


WEST HAVEN, Conn., Feb. 17, 2015 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported that Midtown Partners, Inc., ("Midtown") has published a research report on NanoViricides on February 11, 2014, according to Midtown's website. The report can be found on their website at http://www.midtownpartners.com under the "Research" tab.


Midtown initiated research coverage with a "Strong Buy" rating on NanoViricides with this report. The Company did not pay Midtown any fees or commissions for this research report. Previously, the banking arm of Midtown Partners has helped raise financing for NanoViricides in various investment banking engagements, wherein Midtown earned and was paid commissions and/or fees according to the appropriate engagement agreements in force, most recently in January 2014. Chardan Capital Markets, LLC, acted as lead placement agent and Midtown Partners was the co-placement agent in connection with this January 2014 registered direct offering.

Midtown's research analysts interviewed NanoViricides' executives for this report. Midtown research analysts also performed substantial additional independent research.

The Company does not comment on, and does neither endorse nor dispute any such third party research.